Intentional R1 resection of liver metastases: A new treatment paradigm for patients with advanced colorectal cancer based on a propensity score-Matched case-control analysis.


Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
04 2023
Historique:
received: 21 12 2022
revised: 07 02 2023
accepted: 17 02 2023
medline: 4 4 2023
pubmed: 23 2 2023
entrez: 22 2 2023
Statut: ppublish

Résumé

Clinical outcomes of colorectal cancer (CRC) patients after an incomplete microscopic (R1) resection of liver metastases may not differ from those following a microscopically margin negative (R0) resection, when the latest is not feasible because of anatomic issues. We aimed at comparing the clinical outcomes of CRC patients with an intentional R1 or with a R0 resection of liver metastases. All patients with advanced in CRC and liver metastases consecutively treated by liver resection between February 2005 and January 2019 at in the department of Digestive and Hepatobiliary Surgery of Henri Mondor University Hospital (Créteil, France) were included in this retrospective case-control study. Overall survival (OS) and event-free survival (EFS) were compared between patients who underwent an intentional (pre-operative decision) R1 resection (iR1) to those who had a R0 resection of liver metastases. To account for confounding, comparison between the 2 groups was performed after adjustment using propensity score analysis. Twenty-six CRC patients treated by iR1 resection of liver metastases were compared to 98 patients treated by R0 resection. Median OS reached 39 months [95% confidence interval (CI): 25-67] and 63 months [95% CI: 52-76] in the iR1 and R0 groups, respectively. After adjustment by inverse probability of treatment weighting, patients' OS and EFS did not differ significantly between the iR1 and R0 groups (hazard ratio (HR): 1.19 [0.54-2.62] and 1.67 [0.93-3.03]), respectively. iR1 resection of liver metastases in advanced CRC patients is an acceptable therapeutic strategy, when R0 resection is not feasible.

Sections du résumé

BACKGROUND
Clinical outcomes of colorectal cancer (CRC) patients after an incomplete microscopic (R1) resection of liver metastases may not differ from those following a microscopically margin negative (R0) resection, when the latest is not feasible because of anatomic issues. We aimed at comparing the clinical outcomes of CRC patients with an intentional R1 or with a R0 resection of liver metastases.
METHODS
All patients with advanced in CRC and liver metastases consecutively treated by liver resection between February 2005 and January 2019 at in the department of Digestive and Hepatobiliary Surgery of Henri Mondor University Hospital (Créteil, France) were included in this retrospective case-control study. Overall survival (OS) and event-free survival (EFS) were compared between patients who underwent an intentional (pre-operative decision) R1 resection (iR1) to those who had a R0 resection of liver metastases. To account for confounding, comparison between the 2 groups was performed after adjustment using propensity score analysis.
RESULTS
Twenty-six CRC patients treated by iR1 resection of liver metastases were compared to 98 patients treated by R0 resection. Median OS reached 39 months [95% confidence interval (CI): 25-67] and 63 months [95% CI: 52-76] in the iR1 and R0 groups, respectively. After adjustment by inverse probability of treatment weighting, patients' OS and EFS did not differ significantly between the iR1 and R0 groups (hazard ratio (HR): 1.19 [0.54-2.62] and 1.67 [0.93-3.03]), respectively.
CONCLUSION
iR1 resection of liver metastases in advanced CRC patients is an acceptable therapeutic strategy, when R0 resection is not feasible.

Identifiants

pubmed: 36804451
pii: S2210-7401(23)00022-0
doi: 10.1016/j.clinre.2023.102097
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102097

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflicts of interest to disclose.

Auteurs

Anaïs Jenvrin (A)

Assistance Publique - Hôpitaux de Paris (APHP), Henri Mondor University Hospital, Department of Medical Oncology, Créteil, France.

Athéna Galletto-Pregliasco (A)

APHP, Henri Mondor University Hospital, Department of Radiology, Créteil, France.

Etienne Audureau (E)

Université Paris-Est Créteil (UPEC), INSERM Unite U 955 Equipe CEpiA, APHP, Henri Mondor University Hospital, Department of Public Health, Créteil, France.

Anaïs Pujals (A)

UPEC, INSERM Unité U 955 Equipe 9, APHP, Department of Pathology, Henri Mondor University Hospital, Créteil, France.

Loëtitia Favre (L)

UPEC, INSERM Unité U 955 Equipe 9, APHP, Department of Pathology, Henri Mondor University Hospital, Créteil, France.

Alain Luciani (A)

UPEC, INSERM Unite U 955 Equipe 18, APHP, Henri Mondor University Hospital, Department of Radiology, Créteil, France.

Julien Calderaro (J)

UPEC, INSERM Unité U 955 Equipe 18, APHP, Department of Pathology, Henri Mondor University Hospital, Créteil, France.

Daniele Sommacale (D)

UPEC, INSERM Unite U 955 Equipe 18, APHP, Henri Mondor University Hospital, Department of Digestive and Hepatobiliary Surgery, Créteil, France.

Gilles Chatellier (G)

Université Paris Cité, APHP, Department of Medical Information, Paris, France.

Christophe Tournigand (C)

Assistance Publique - Hôpitaux de Paris (APHP), Henri Mondor University Hospital, Department of Medical Oncology, Créteil, France; UPEC, INSERM, IMRB, F-94010, APHP, Henri Mondor University Hospital, Department of Medical Oncology, Créteil, France.

Alexis Laurent (A)

UPEC, INSERM Unite U 955 Equipe 18, APHP, Henri Mondor University Hospital, Department of Digestive and Hepatobiliary Surgery, Créteil, France.

Emmanuelle Kempf (E)

Assistance Publique - Hôpitaux de Paris (APHP), Henri Mondor University Hospital, Department of Medical Oncology, Créteil, France. Electronic address: emmanuelle.kempf@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH